Clinical research into age-related macular degeneration (AMD) is highly active across the UK, with numerous trials currently investigating next-generation therapies. These studies are essential for developing treatments for the “dry” form of the disease, for which there is currently no standard clinical cure, as well as for improving the delivery and longevity of treatments for “wet” AMD. Participating in a clinical trial allows patients to access cutting-edge medical interventions while contributing to research that could benefit thousands of others. Most UK-based trials are hosted by specialist NHS eye hospitals and academic institutions, ensuring they meet rigorous ethical and safety standards.
What We’ll Discuss in This Article
- Current research into gene therapy for both dry and wet AMD.
- The development of electronic retinal implants to restore functional sight.
- New long-acting medications and delivery systems for wet AMD.
- How to find and join active studies through the NIHR “Be Part of Research” service.
- The role of the Macular Society and Moorfields Eye Hospital in UK research.
- The clinical process of screening and participating in an eye-related study.
Investigational gene therapy for dry AMD
One of the most promising areas of research in the UK involves gene therapy designed to halt the progression of geographic atrophy, an advanced form of dry AMD. These trials typically involve a one-time surgical injection of a viral vector directly under the retina. The goal is to “reprogramme” retinal cells to produce specific proteins that reduce inflammation or protect the cells from further decay.
A notable example is the ongoing research into therapies like GT005, which has been tested at sites such as Manchester Royal Eye Hospital and the John Radcliffe Hospital in Oxford. According to research updates from the University of Oxford, these trials focus on counteracting the overactive complement system, which is believed to drive the inflammation seen in dry AMD. While these treatments are still in the investigational phase, they represent a significant shift toward finding a biological solution for a previously untreatable condition.
Breakthroughs in electronic retinal implants
For patients with very advanced dry AMD who have lost most of their central vision, UK researchers are trialling “artificial vision” technologies. The PRIMA system, a subretinal micro-chip implant, has recently shown remarkable results in clinical trials led by Moorfields Eye Hospital NHS Foundation Trust. This technology works by converting infrared light from special augmented-reality glasses into electrical signals that the brain interprets as vision.
In recent trial results, a high percentage of participants regained the ability to recognise letters and words, which significantly improved their independence. Although this device is not yet available as a standard NHS treatment, the success of these trials is a pivotal step toward restoring functional sight. These studies are often “first-in-human” or early-phase trials, meaning they are closely monitored for both safety and efficacy.
New delivery systems for wet AMD
Clinical trials for wet AMD currently focus on reducing the “treatment burden” for patients who require frequent eye injections. Research is underway to test longer-acting drugs and permanent delivery systems that can release medication over several months. This includes the Port Delivery System; a refillable reservoir implanted in the eye that gradually releases anti-VEGF medication.
Other trials are investigating high-dose versions of existing medications, such as 8mg aflibercept, to see if they can extend the time between hospital visits from the standard 4-8 weeks to up to 16 weeks or more. By participating in these trials, patients help clinicians determine which protocols provide the best balance between vision preservation and patient convenience.
How to find and join a clinical trial
The primary way for patients in the UK to find clinical trials is through the National Institute for Health and Care Research (NIHR). The “Be Part of Research” service is a central database that allows individuals to search for studies by condition and location. You can register your interest and be matched with suitable trials as they become available in your area.
For those specifically interested in eye health, the Macular Society research participant database is an excellent resource. By signing up, you can be notified of opportunities ranging from simple surveys to complex clinical drug trials. It is always recommended to discuss your interest in research with your local ophthalmologist, as a formal referral is often required for hospital-based clinical trials.
The screening and participation process
Participating in a clinical trial is a voluntary process that involves several stages to ensure patient safety. If you find a trial you are interested in, you will first undergo a “screening” phase. This involves detailed eye examinations, blood tests, and sometimes genetic testing to see if you meet the specific “inclusion criteria” for the study. These criteria are very strict to ensure the results of the trial are scientifically valid.
Once enrolled, you will be closely monitored by a team of research nurses and specialist doctors. In many trials, participants are randomly assigned to either the group receiving the new treatment or a “control” group receiving the current standard care. It is important to remember that:
- You can withdraw from a trial at any time without it affecting your regular NHS care.
- Travel expenses for trial-related visits are often reimbursed.
- Trials provide the data necessary for the MHRA and NICE to approve new treatments for general use.
Current Research Areas in the UK
| Research Type | Target Condition | Potential Benefit |
| Gene Therapy | Dry AMD / GA | Halting cell death and inflammation |
| Retinal Implants | Advanced Dry AMD | Restoring central vision/reading ability |
| Long-acting Drugs | Wet AMD | Fewer injections and hospital visits |
| Stem Cell Therapy | Dry & Wet AMD | Replacing damaged retinal cells |
| Oral Medications | Dry AMD | Systemic protection of the macula |
Conclusion
There are several clinical trials currently active in the UK for new AMD treatments, covering everything from advanced gene therapy to electronic implants. These studies represent the forefront of ophthalmological science and offer hope for future treatments that can slow, stop, or even partially reverse vision loss. If you experience severe, sudden, or worsening symptoms, call 999 immediately.
Is there a cost to take part in a clinical trial?
No, clinical trials are free to participate in, and many studies provide reimbursement for travel and subsistence costs related to hospital visits.
Can I take part in a trial if I am over 80?
Yes, age is rarely a barrier to participation, as AMD primarily affects older adults; however, you must meet the specific health criteria for each study.
Will I definitely get the new treatment if I join a trial?
Not necessarily, as many trials are “randomised,” meaning some participants receive the new treatment while others receive the current standard care for comparison.
Do I need my GP’s permission to join?
While you don’t necessarily need permission, it is best practice to inform your GP and ophthalmologist, as they may need to provide your medical history to the research team.
Are there trials for the early stages of AMD?
Yes, some trials focus on prevention or early intervention to stop the disease from progressing into the more advanced stages.
What happens if I have a side effect during a trial?
You will be monitored very closely by the research team, and any side effects are recorded and managed immediately as part of the trial’s safety protocol.
Can I join more than one clinical trial at a time?
No, for safety and data accuracy, you are usually only allowed to participate in one interventional clinical trial at a time.
Authority Snapshot
This article provides up-to-date information on the landscape of AMD clinical research in the UK. The content is based on official data from the NIHR, the NHS, and established research institutions like Moorfields Eye Hospital and the University of Oxford. It is reviewed by the Medical Content Team to ensure patients receive accurate, conservative, and safety-focused information about participating in medical research.
